Weinstock, Leonard B.
Brook, Jill B.
Molderings, Gerhard J.
Funding for this research was provided by:
Universitätsklinikum Bonn
Universitätsklinikum Bonn
Article History
Received: 13 April 2022
Accepted: 11 August 2022
First Online: 19 August 2022
Declarations
:
: The study was reviewed by the Sterling Investigational Review Board (IRB) in Atlanta, Georgia. The Sterling IRB Chairperson decided that the study (ID #9768) was exempt from full IRB review pursuant to the terms of the U.S. Department of Health and Human Service’s Policy for Protection of Human Research Subjects at 45 C.F.R. §46.104(d). The IRB found that the exemption Category 2 applied.
: All patients signed an informed consent form that described all risks of HU and allowed collection and reporting of their clinical data.
: Dr. Weinstock is an uncompensated, volunteer medical advisor to the startup company <i>MC Sciences, Ltd</i>. Dr. Weinstock is a compensated medical advisor to <i>Statera BioPharma</i>. Mrs. Brook has no disclosures. Dr. Molderings is the co-founder and chief medical officer of the startup company <i>MC Sciences, Ltd</i>.